GCC male Fabry prevalence runs 1:20,000-30,000, nearly double the global rate, yet only 200-300 patients are diagnosed against a true burden estimated 3-5 times higher.
Classic Fabry disease prevalence in GCC males is estimated at 1:20,000-30,000, compared with roughly 1:40,000 globally, elevated by Arabian Peninsula founder mutations documented at KFSH&RC that concentrate in consanguineous family clusters. Against that elevated true prevalence, total diagnosed Fabry patients across the GCC number approximately 200-300 in NPHC and specialist registries, a population the KFSH&RC Fabry registry and the broader GCC lysosomal storage disorder network estimate is 3-5 times smaller than the true burden. The gap between the elevated prevalence rate and the modest diagnosed count is this funnel's first and largest narrowing point, and it is a diagnostic gap, not a treatment-access one.
Family-based cascade screening after an index diagnosis is the highest-yield tool for closing that gap: the KFSH&RC Fabry registry has documented more than 15 unique founder-mutation family clusters, and cascade screening at index-case diagnosis identifies an estimated 3-5 additional affected members per family. That yield is markedly uneven by sex. Estimated female Fabry burden in the GCC runs 2-3 times the male burden, yet diagnosed female cases represent fewer than half the male diagnosis rate, because women are rarely offered cascade screening after a male relative's diagnosis and cultural factors in some families further limit female genetic workup. The female-diagnosis gap is therefore the single largest under-identified segment of this funnel.
GCC Fabry funnel — from elevated founder-mutation prevalence to the diagnosed population
| Funnel Stage | Population | Source |
|---|---|---|
| Male Fabry prevalence rate (GCC, est.) | 1:20,000-30,000 | Al-Hassnan ZN, Saudi Med J 2010; KFSH&RC Fabry disease registry 2023 |
| Global male Fabry prevalence (comparator) | 1:40,000 | NORD / global Fabry registry epidemiology |
| Diagnosed GCC Fabry patients (NPHC / specialist registries) | 200-300 | NPHC Fabry disease programme guidelines 2023; KFSH&RC Fabry disease registry 2023 |
| Estimated true GCC Fabry prevalence | 3-5x diagnosed | KFSH&RC Fabry cohort retrospective 2019; GCC lysosomal storage disorder network 2022 |
| Additional affected family members identified via cascade screening | 3-5 per index case; 15+ documented founder-mutation clusters | KFSH&RC Fabry disease registry 2023 |
| Female diagnosis rate relative to male | <50% of male rate, vs an estimated 2-3x higher female burden | KFSH&RC Fabry genetics programme data; GCC lysosomal storage disorder network 2022 |
Sources: Al-Hassnan ZN, Saudi Med J 2010; KFSH&RC Fabry disease registry 2023; KFSH&RC Fabry cohort retrospective 2019; NPHC Fabry disease programme guidelines 2023; GCC lysosomal storage disorder network 2022; KFSH&RC Fabry genetics programme data.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- GCC male prevalence rate (1:20,000-30,000) versus the global 1:40,000 comparator
- diagnosed population (200-300) versus true prevalence estimated 3-5x higher
- founder-mutation cluster mapping (15+ documented at KFSH&RC)
Delivers
- Cascade-screening yield of 3-5 additional affected family members per index case
- the founder-mutation cluster structure driving that yield
- cascade screening framed as the highest-yield diagnostic strategy available
Delivers
- Female diagnosis rate under 50% of the male rate
- estimated female disease burden 2-3x the male burden
- the cascade-screening gap on female relatives that drives the shortfall
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the diagnostic gap, not treatment access, is the funnel's binding constraint
- Pressure-tested against KFSH&RC registry and European Fabry registry comparators
- 1:20,000-30,000 GCC male prevalence versus 1:40,000 globally (Al-Hassnan / KFSH&RC)
- Arabian Peninsula founder-mutation family cluster structure
- 200-300 diagnosed patients against a true prevalence estimated 3-5x higher
- Cascade screening yield of 3-5 additional members per family
- Female diagnosis rate under 50% of the male rate
- Estimated female burden 2-3x the male burden, and why it is under-identified
- NPHC coverage status for enzyme replacement and migalastat
- The HEK293 assay bottleneck limiting oral-chaperone eligibility confirmation
- Which cascade-yield and female-diagnosis assumptions move the eligible pool most
- Scenario ranges across diagnosed and true-prevalence estimates
- Patient volume by horizon under conservative, base, and aggressive scenarios
- Revenue translation inputs
- Open questions your forecasting team must close before the model is finalized
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and capture (E2), treatment and eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Delivered as a live Excel workbook, not a static table: 108 formulas across 8 sheets, zero hardcoded cells.
This model is built from the KFSH&RC Fabry disease registry, KFSH&RC Fabry cohort retrospective data, NPHC Fabry disease programme guidelines, and the GCC lysosomal storage disorder network, triangulated against European and global Fabry registry comparators to isolate the GCC-specific prevalence elevation and diagnostic gap.
- GCC male prevalence and founder-mutation figures verified against Al-Hassnan ZN, Saudi Med J 2010 and KFSH&RC Fabry disease registry 2023
- Diagnosed-versus-true-prevalence ratio verified against KFSH&RC Fabry cohort retrospective 2019 and GCC lysosomal storage disorder network 2022
- Cascade-screening yield and founder-mutation cluster count verified against KFSH&RC Fabry disease registry 2023
- Female diagnosis gap figures verified against KFSH&RC Fabry genetics programme data and GCC lysosomal storage disorder network 2022
Frequently asked questions
Commission this model
AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC Fabry disease opportunity. Custom model in 72 hours.
Specify your indication, GCC country focus, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.